09 Oct [MCE] High-throughput screening of Drugs for the treatment of neurodegenerative diseases (NDDs)
The pathogenesis of neurodegenerative diseases (NDD) are mainly caused by the loss of functions of neurons in the central nervous system or peripheral nervous system, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Spinocerebellar ataxia (SCA), Spinal muscular atrophy (SMA), and Amyotrophic lateral sclerosis (ALS), etc[1]. Neurodegenerative diseases profoundly impact the lives of millions, impairing memory, cognition, behavior, sensory, and motor functions.
Figure 1. The hallmarks of NDDs at the subcellular level[1].While significant progress has been made in unravelling the pathologic mechanism of neurodegenerative diseases, many pharmacological targets remain elusive and require further validation to treat neurodegenerative disorders. In recent years high-throughput screening (HTS) and high-content screening (HCS) technologies have been widely applied to investigate the mechanisms of neurodegenerative diseases. For example, PD is characterized by the formation of Lewy bodies, resulting from the abnormal deposition of alpha-synuclein (α-syn). And in Lund human mesencephalic cell model, Casalino et al. screened α-syn protein inhibitor 6-diazo-5-oxo-l-nor-leucine (DON) by high-throughput screening luciferase report assay[2]. In addition, in the induced pluripotent stem cell model derived from Parkinson’s disease patients, Antoniou et al. also identified the neuroprotective kinase inhibitor BX795 through high-content screening[3].The MCE neurodegenerative diseases libraries serve as valuable resources for investigating the underlying mechanisms of neurodegenerative diseases and the discovery of innovative therapeutic agents.
MedChemExpress —
Master of Bioactive MoleculesThe MCE Neurodegenerative Diseases Libraries
| Product Name | Description |
Neurodegenerative Disease-related Compound Library |
1,800+ compounds with anti-neurodegenerative diseases activities or targeting the unique targets of neurodegenerative diseases. |
Anti-Parkinson’s Disease Compound Library |
1,100+ compounds with anti-Parkinson’s Disease (PD) activities or targeting the unique targets of PD. |
Neuronal Signaling Compound Library |
2,200+ neuronal signaling-related compounds that acts as a useful tool for the research of neuronal regulation and neuronal diseases. |
Neuroprotective Compound Library |
900+ compounds targeting major targets in neuroprotective pathways such as calcium channel, sodium channel, adenosine A1 receptor, etc. |
Neurotransmitter Receptor Compound Library |
1,600+ neurotransmitter receptor-related compounds, which is an effective tool for drug screening for neurological diseases. |
CNS-Penetrant Compound Library |
700+ compounds with confirmed CNS-Penetrant properties which is a useful tool for discovering drugs of brain diseases such as brain tumors, mental disorders, and neurodegenerative diseases, etc. |
5-HT Receptor Compound Library |
200+ 5-HT receptor inhibitors and activators which can be used for neuropsychiatric disorders drugs discovery. |
More compound libraries are available in MCE:
https://www.medchemexpress.com/screening-libraries.html
References:
[1] Cell. 2023;186(4):693-714.
[2] SLAS Discov. 2022 Sep;27(6):349-357.
[3] NPJ Parkinsons Dis. 2022 Feb 11;8(1):15.
Request Your Quote